

# Charbel Moussa Mbbs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3359321/publications.pdf>

Version: 2024-02-01

38  
papers

2,063  
citations

304743

22  
h-index

361022

35  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3000  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	3.7	6
2	Long-term Safety and Clinical Effects of Nilotinib in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 740-749.	3.9	32
3	Reply to "Cardiovascular Safety of Nilotinib in Alzheimer's Disease". <i>Annals of Neurology</i> , 2021, 89, 196-197.	5.3	0
4	Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases. <i>Neuroscience</i> , 2021, 460, 161-166.	2.3	13
5	Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology. <i>Metabolites</i> , 2021, 11, 622.	2.9	12
6	CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease. <i>Neurology: Genetics</i> , 2021, 7, e633.	1.9	12
7	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	2.4	12
8	Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 309.	9.0	108
9	Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases. <i>Human Molecular Genetics</i> , 2020, 29, 2882-2898.	2.9	28
10	Can sex influence the neurocognition of language? Evidence from Parkinson's disease. <i>Neuropsychologia</i> , 2020, 148, 107633.	1.6	5
11	Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease. <i>Annals of Neurology</i> , 2020, 88, 183-194.	5.3	73
12	Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease"Reply. <i>JAMA Neurology</i> , 2020, 77, 1039.	9.0	2
13	Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 425-441.	2.6	21
14	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 23.	6.2	9
15	Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. <i>Drugs in R and D</i> , 2019, 19, 149-166.	2.2	42
16	Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00470.	2.4	71
17	Autophagy in Neurodegenerative Diseases. <i>Cancer Drug Discovery and Development</i> , 2019, , 197-212.	0.4	0
18	Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 1-11.	5.9	45

#	ARTICLE	IF	CITATIONS
19	Author's Reply to Segura-Aguilar: Autophagosome maturation not autophagy induction is impaired in neurodegeneration. <i>CNS Drugs</i> , 2018, 32, 687-688.	5.9	0
20	Tau clearance improves astrocytic function and brain glutamate-glutamine cycle. <i>Journal of the Neurological Sciences</i> , 2018, 391, 90-99.	0.6	39
21	Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2017, 14, 1.	7.2	544
22	Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. <i>Journal of Neuroimmunology</i> , 2017, 311, 1-9.	2.3	43
23	Resveratrol for Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2017, 1403, 142-149.	3.8	198
24	Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1131-1136.	4.1	44
25	Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. <i>Journal of Parkinson's Disease</i> , 2016, 6, 503-517.	2.8	193
26	Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid homeostasis. <i>Journal of Neurochemistry</i> , 2016, 139, 610-623.	3.9	30
27	Could cancer drugs be repurposed for use in Parkinson's and Alzheimer's?. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1335-1336.	2.8	0
28	Tau deletion impairs intracellular $\beta$ -amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. <i>Molecular Neurodegeneration</i> , 2014, 9, 46.	10.8	42
29	Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. <i>Journal of Molecular Medicine</i> , 2014, 92, 373-386.	3.9	122
30	Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis. <i>Journal of Neurochemistry</i> , 2014, 129, 350-361.	3.9	32
31	Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. <i>Human Molecular Genetics</i> , 2014, 23, 4960-4969.	2.9	36
32	Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and $A\beta$ 1-42 gene transfer models. <i>Experimental Neurology</i> , 2014, 251, 127-138.	4.1	13
33	Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1571-1579.	1.4	4
34	Tyrosine kinase inhibition facilitates autophagic SNCA/ $\alpha$ -synuclein clearance. <i>Autophagy</i> , 2013, 9, 1249-1250.	9.1	53
35	Ubiquitination Increases Parkin Activity to Promote Autophagic $\alpha$ -Synuclein Clearance. <i>PLoS ONE</i> , 2013, 8, e83914.	2.5	69
36	Parkin prevents cortical atrophy and $A\beta$ -induced alterations of brain metabolism: $^{13}C$ NMR and magnetic resonance imaging studies in AD models. <i>Neuroscience</i> , 2012, 225, 22-34.	2.3	22

#	ARTICLE	IF	CITATIONS
37	The ubiquitin ligase parkin modulates the execution of autophagy. <i>Autophagy</i> , 2011, 7, 919-921.	9.1	18
38	Parkin Attenuates Wild-Type $\beta$ , Modification in the Presence of $\beta$ -Amyloid and $\alpha$ -Synuclein. <i>Journal of Molecular Neuroscience</i> , 2009, 37, 25-36.	2.3	19